Revolution Medicines Inc (RVMD NASDAQ) stock market data APIs
$61.8031
-2.63(-4.3%)
as of November 6, 2025
Try our APIs with
free plan!
Revolution Medicines Inc Financial Data Overview
Price chart is built with
Anychart
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Prev. Close
61.8031
Open
59.1748
High
63.6649
Low
59.0319
52 wk Range
29.17-63.15
Market Cap
11 866 M
Shares Outstanding
193 M
Revenue
742 K
EPS
-1.61
Beta
0.989
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Revolution Medicines Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Revolution Medicines Inc data using free add-ons & libraries
Get Revolution Medicines Inc Fundamental Data
Revolution Medicines Inc Fundamental data includes:
- Net Revenue: 742 K
- EBITDA: -890 700 032
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -1.41
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Revolution Medicines Inc News
New
Revolution Medicines (RVMD): Assessing Valuation After Recent 28% Monthly Share Price Surge
Revolution Medicines (RVMD) has been catching attention, with shares moving up 3% in the past day and gaining 28% in the last month. Investors seem curious about what is fueling this change, especiall...
Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil
Revolution Medicines RVMD reported a third-quarter 2025 loss of $1.61 per share, wider than the Zacks Consensus Estimate of a loss of $1.39. The company had incurred a loss of 94 cents in the year-ago...
Revolution Medicines Inc (RVMD) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...
This article first appeared on GuruFocus. Cash and Investments: $1.93 billion at the end of Q3 2025. R&D Expenses: $262.5 million for Q3 2025, up from $151.8 million in Q3 2024. G&A Expenses: $52.8 m...
Revolution Medicines outlines multiple Phase III trial launches and commercial buildout amid increased R&D investment
Earnings Call Insights: Revolution Medicines (RVMD) Q3 2025 MANAGEMENT VIEW * CEO Mark Goldsmith opened the call highlighting the company's ongoing commitment to “revolutionizing treatment for p...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
